NL-OMON30750尚未招募2 期
A single centre, double blind, randomised, parallel group study to explore the efficacy and tolerability of intranasal fluticasone propionate compared with placebo delivered by the OptiNose device in adult subjects with chronic rhinosinusitis. - OptiNose Intranasal Fluticasone Propionate and Chronic Rhinosinusitis
OptiNose UK Ltd0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Male and female subjects aged between 18 and 65 years of age.
- •- Subjects must have chronic rhinosinusitis which is defined as at least 12 weeks history of two or more of:
- •* Blockage/congestion
- •* Discharge: anterior/post nasal drip
- •* Facial pain/pressured
- •* Reduction or loss of smell
- •And either:
- •* Mucopurulent discharge from the middle meatus or
- •* Edema/mucosal obstruction primarily in the middle meatus.
- •- Subjects must have no clinically significant abnormal serum biochemistry, haematology and urine examination values on screening.
- •- Subjects must have verified airflow through both nostrils and an ability to close their soft palate.
- •- The subject must have the ability to create bi-directional flow using a placebo OptiNose device with a nasal outflow of >20 L/min.
- •- The subject must have the ability to trigger the Breath Actuation Mechanism of an OptiNose device in accordance with the Instructions For Use.
排除标准
- •- Subjects who have visible pedunculated polyps on nasal endoscopy.
- •- Subjects who have undergone surgical treatment for nasal polyps during the previous 3 months.
- •- Subjects with a diagnosis of cystic fibrosis.
- •- Subjects with other disease likely to interfere with the study parameters, evidence of any serious or unstable concurrent disease or psychological disorder.
- •- A hypersensitivity or contraindication to steroids or any excipients.
- •- Subjects who have received depot or oral steroids during the previous 3 months.
- •- Subjects with a requirement for more than 1000 µg beclomethasone (or equivalent) per day for the treatment of asthma.
- •- Subjects taking inhaled steroids who have not been on a stable dose for 3 months or more.
- •- Subjects who are unable to cease treatment with intranasal steroids, or intranasal sodium cromoglycate, decongestants or antihistamines at the Screening Visit.
- •- Subjects currently receiving leukotriene receptor antagonists, nasal atropine or ipratropium bromide, beta blockers or neuroleptics.
- •- Subjects who are unable to cease treatment with saline rinsing at the Screening Visit.
- •- Subjects using devices that dilate the nostrils to improve nasal breathing.
- •- Subjects being treated with ritonavir or other potent CYP3A inhibitors as listed in Appendix 2 of the protocol due to the potential for greatly increased fluticasone plasma concentrations.
- •- Subjects with a history of operations where metal objects were used and retained in the body or those with a pacemaker or other implants e.g. cochlear implants and artificial heart valves.
- •- Subjects with a history of a penetrating injury to the eye with a metal object or those who have worked with metal at high speed.
- •- A history of drug or alcohol abuse.
- •- Subjects with an inability to communicate well with the investigator (i.e. language problem,poor mental development or impaired cerebral function)
- •- Subjects with a cleft palate.
- •- Subjects who have participated in a New Chemical Entity study within the previous 16 weeks or a marketed drug study within the previous 12 weeks.
研究者
相似试验
撤回
1 期
A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in participants with DSM-5 specific phobiaSpecific phobia to spidersMental Health - Other mental health disordersACTRN12618001381279Douglas Pharmaceuticals Ltd12
已完成
1 期
A single and multiple dose safety and tolerability study of oral ketamine in healthy volunteer and patients with a history of depression or anxiety.Mental Health - DepressionMental Health - AnxietyDepressionAnxietyACTRN12616001351404Zenith Technology Corp Ltd43
招募中
不适用
Clinical study of efficacy and safety of Chung A Won in Women’s patients with osteoporosisDiseases of the musculo-skeletal system and connective tissueKCT0000594Cheonan Korean Medicine Hospital of Daejeon University106
已完成
3 期
A clinical study to test the effect of 2 product formulations against a control, on gingival conditions and plaque levels, in an experimental gingivitis model after 3 weeks of home use.CTRI/2009/091/000626Smile Care Clinic Pvt Ltd100
进行中（未招募）
1 期
A single centre, randomised, single blind, parallel group single dose study to compare the speed of onset of ibuprofen gel, ibuprofen gel with levomenthol and diclofenac gel in the relief of pain from strains, sprains and sports injuriesPain of strains, sprains and sports injuriesMedDRA version: 18.1 Level: PT Classification code 10065016 Term: Post-traumatic pain System Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2015-005240-33-GBThe Mentholatum Company Ltd182